Gitelman Syndrome Market Research Report, By Diagnosis (Urine Electrolytes Tests, Molecular Genetic Tests), By Treatment (Supplements, Medication), By End User (Hospitals & Clinics, Diagnostic Labs, Research Organization- Global Forecast till 2030

Gitelman Syndrome Market Scenario:

The Gitelman syndrome market is projected to reach USD 1,000,90 Million by 2030 at 12.60% CAGR during the forecast period 2022-2030.Gitelman syndrome is a rare type of genetic disorder of the kidneys. It causes an imbalance of potassium, magnesium, and calcium ions within the patient’s body. Tetany, paresthesias, and fatigue are some of the common symptoms of Gitelman syndrome. The signs and symptoms of Gitelman syndrome usually appear in the late childhood or adolescence. According to the Genetics Home Reference (2018), it is estimated that the disease affects 1 in 40,000 people worldwide. Increasing global burden of chronic kidney diseases and growing biotechnology sector are the major drivers of the market. According to the International Society of Nephrology in 2015, the global mortality rate of chronic kidney diseases increased between 2005 and 2015 by 32%. This was estimated to account for 1.2 million deaths worldwide within the same year. Moreover, growing adolescent population and increased R&D expenses by the key players are estimated to boost the market growth during the projected period. According to the Child Trends, the number of the children under 18 years of age is projected to increase from 74.1 million to 78.2 million by 2040. However, factors such as stringent FDA approvals followed by the limited availability of the diagnostic and treatment options, low per capita healthcare expenditure, and lack of awareness are estimated to be the major restrains for the market growth during the forecasted period. 

Intended Audience

• Pharmaceutical Companies


• Biotechnological Institutes


• Government and Private Laboratories


• Research And Development (R&D) Companies


• Medical Research Laboratories


• Market Research And Consulting Service Providers 

Figure 1:- Global Gitelman Syndrome Market share, by Region

Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The Gitelman syndrome market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of the diagnosis, the market is segmented into urine electrolytes tests, molecular genetic tests, and others. The urine electrolytes tests are sub-segmented into sodium test, potassium test, chloride test, and others. The molecular genetic tests are sub-segmented into PCR (Polymerase Chain Reaction) hybridization and others.

On the basis of the treatment, the market is segmented into supplements, medication, and others. The supplements segment is sub-segmented into potassium supplement, magnesium supplement, and others. The medication segment is sub-segmented with diuretics and anti-inflammatory drugs (NSAIDS). The diuretics segment by medication is further segmented into spironolactone, amiloride, and others. The NSAIDS segment, by medication, is further segmented into ibuprofen, indomethacin, and others.

On the basis of the end user, the Gitelman Syndrome Market is segmented into hospitals & clinics, diagnostic labs, research organization, and others. 

Regional Analysis 

The Americas dominate the Gitelman syndrome market owing to a well-developed healthcare sector, increasing the prevalence of chronic kidney diseases, and rising adolescent population. Additionally, changing lifestyle and presence of the developed economies like the U.S. and Canada within the region boost the market growth within the America region. 

Europe is the second largest Gitelman syndrome market and is followed by the Asia Pacific. Availability of funds for research, the huge patient population having chronic kidney diseases along with rising government support for research & development are driving the market growth. According to the British Kidney Patient Association in 2018, approximately 1 in every 8 people in the U.K are estimated to develop chronic kidney disease (CKD). 

The Asia Pacific is the fastest growing region in global the market due to the presence of a huge patient population and continuously developing economies like India and China, which have developing healthcare sector and rising healthcare expenditure. Moreover, growing biotechnology sector is boosting the market growth within the region. According to the Indian Brand Equity Foundation in 2017, the Indian biotechnology sector holds approximately 2.0% of the total biotechnology sector and is estimated to be a USD 100 billion industry by 2025. 

On the other hand, the Middle East & Africa owns the least share of the Gitelman syndrome market due to the presence of poor economies, especially in the Africa region. Moreover, stringent government policies hinder the market growth within the region. The Middle East holds a major share of the market due to the well-developed healthcare sector and the presence of developed economies within the region. 

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation 

Key players in Gitelman syndrome market

Some of the key players in the Gitelman syndrome market are Pfizer Inc. (U.S.), Hisoar (China), Taj Pharmaceuticals Ltd. (India), Merck & Co., Inc. (U.S.), Xinhua Pharm (China), BIOCAUSE Inc. (China), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Germany), Abbott (U.S.), Danaher (U.S.), Agilent Technologies (U.S.), and others.